Is It Time To Reassess Synopsys (SNPS) After The Recent Share Price Pullback

  • Investors may be considering whether Synopsys at around US$396 a share still offers value, or if better opportunities lie elsewhere in the software space.
  • The stock is down 4.6% over the last 7 days, 4.2% over the past month, and 17.5% year to date, with a 9.1% decline over 1 year that contrasts with a 54.1% gain over 5 years.
  • Recent coverage has focused on Synopsys as a key player in electronic design automation and semiconductor software. Investors are paying close attention to how demand for chip design tools and related software shapes sentiment. This context helps frame whether the latest share price pullback reflects changing risk views or simply a reset after strong multi year returns.
  • On Simply Wall St’s 6 point valuation check, Synopsys scores 1 out of 6. Next up is a look at how different valuation methods stack up for the stock and how a broader way of thinking about value could matter even more by the end of this article.

Synopsys scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Advertisement

Approach 1: Synopsys Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows, discounts them back to today using a required return, and adds them up to estimate what the business might be worth right now.

For Synopsys, the latest twelve month Free Cash Flow is about US$2.24b. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates point to Free Cash Flow of US$4.56b in 2030, with a series of projections in between. Simply Wall St uses analyst forecasts where available, then extends them for later years, all in US$.

On this basis, the DCF model arrives at an estimated intrinsic value of around US$392.49 per share. With the current share price around US$396, the model suggests Synopsys trades at roughly a 1.0% premium to this estimate. This is effectively in the same ballpark rather than a clear bargain or clear excess.

Result: ABOUT RIGHT

Synopsys is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

SNPS Discounted Cash Flow as at Mar 2026
SNPS Discounted Cash Flow as at Mar 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Synopsys.

Approach 2: Synopsys Price vs Earnings

For profitable companies like Synopsys, the P/E ratio is a widely used yardstick because it ties what you pay directly to the earnings the business is currently generating. It helps you see how many dollars of share price you are paying for each dollar of earnings.

What counts as a "normal" P/E depends heavily on what investors expect for future growth and how much risk they see in those earnings. Higher growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower, more conservative multiple.

Synopsys currently trades on a P/E of 68.71x. That is well above the Software industry average of 28.66x and also above the peer group average of 38.82x. Simply Wall St’s proprietary Fair Ratio for Synopsys is 43.10x. This Fair Ratio reflects factors such as earnings growth expectations, profit margins, industry, market cap and risk profile, which makes it more tailored than a simple comparison with peers or the broad industry. Lining up the current P/E of 68.71x against the Fair Ratio of 43.10x suggests the shares trade on a richer multiple than this framework would point to.

Result: OVERVALUED

NasdaqGS:SNPS P/E Ratio as at Mar 2026
NasdaqGS:SNPS P/E Ratio as at Mar 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Synopsys Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are Simply Wall St’s way for you to turn your view of Synopsys into a clear story that links what the business is doing, to a financial forecast, and then to a fair value you can compare with the current share price.

A Narrative lets you combine your assumptions about future revenue, earnings and margins with your view of risks and opportunities. So instead of only looking at a P/E of 68.71x or an analyst fair value of US$537.75, you see how your own numbers translate into a price you would be comfortable paying.

On Simply Wall St’s Community page, Narratives are set up so that when new earnings, news or guidance arrive, the forecasts and fair values refresh automatically. This can help you regularly reassess whether Synopsys looks closer to a buy, a hold or a sell for your situation as its story evolves.

With Synopsys, for example, one investor might lean toward the higher end of analyst views near US$650 if they think Ansys integration, AI related demand and SaaS adoption play out well. Another might sit nearer US$425 if they place more weight on China, IP and integration risks, and Narratives let you see both cases side by side.

Do you think there's more to the story for Synopsys? Head over to our Community to see what others are saying!

NasdaqGS:SNPS 1-Year Stock Price Chart
NasdaqGS:SNPS 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:SNPS

Synopsys

Provides design IP solutions in the semiconductor and electronics industries.

Fair value with moderate growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
186 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0